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C~orot~an~ene (TACE) exhibits in vitro little or no binding to the uterine estrogen receptor (ER) but demonstrates potent estrogenic activity 
in vivo, indicating that TACE is a proestrogen/proantiestrogen. Our earlier studies demonstrated that the incubation of TACE with rat liver micro- 
somes and NADPH generates a reactive intermediate (T*) which binds covalently to proteins. The current study examined the possibility that 
T* may inactivate the uterine ER. The incubation of TACE with rat liver microsomes and NADPH in the presence of rat uteri, under conditions 
which generate T*, markedly decreased the binding capacity of the ER for PH]estradiol (E& The evidence indicates that ER inactivation was 
probably due to irreversible (covalent) binding of T* to the E, binding site. The ~ssibility that the antiestrogenic action of TACE and of other 
triphenylethylenes involves such a novel mechanism is discussed. 
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1. INTRODUCTION 
Since the discovery of the first nonsteroidal anti- 
estrogen [l], numerous studies have been conducted to 
determine the mechanism of action of this class of com- 
pounds. However, despite extensive efforts in many 
laboratories, there is currently no mech~ism which 
adequately explains both the agonistic and antagonistic 
actions of the triphenylethylene compounds [2]. 
Moreover, the pronounced differences in activity 
elicited by tamoxifen in a variety of animal species are 
puzzling; tamoxifen is a pure estrogen agonist in the 
mouse uterus, a partial agonist/antagonist in the rat 
uterus and a pure antagonist in the chick oviduct [3-61. 
Recently it was observed that chlorotri~isene (TACE), 
a long-acting triphenylethylene strogen, exhibits an- 
tiestrogenic activity [7]. These findings indicate that 
triphenylethylene derivatives generally share similarity 
of action and that the differences, such as between 
tamoxifen and TACE, are merely quantitative. In view 
of such findings, it is difficult to envision a unified 
mechanism of action for triphenylethylenes across 
animal species, based solely on the reversible binding to 
the estrogen receptor (ER) or to the antiestrogen 
binding site [ 17,261. Therefore we embarked on a study 
of alternative mechanisms for antiestrogen action. 
Our earlier studies demonstrated that the incubation 
of TACE with rat liver microsomes and NADPH or 
with a reconstituted P-450 monooxygen~e produces a 
reactive intermediate (T*), which binds covalently to 
proteins [12,13]. T* exhibits considerable stability, sug- 
gesting that T* might survive in transport. Hence, it ap- 
peared conceivable that in the course of incubation of 
TACE with liver microsomes and NADPH and uteri, 
T* would react with uterine proteins, possibly with the 
ER. The current study supports this supposition. The 
incubation of TACE with rat liver microsomes in the 
presence of NADPH and immature rat uteri, under 
conditions which generate T*, causes a pronounced 
decrease in the estrogen-binding sites in the uterine ER 
(assayed by exchange with ]3H]estradiol (f3H]E&. Our 
studies suggest hat T* reacts readily with compounds 
containing free sulfhydryl groups [12]. Hence, we 
speculate that the decrease in Ez binding to the ER is 
due to the reaction of T* with cysteines at the estrogen 
binding site of ER [14,18]. The possibility that other 
antiestrogenic triphenylethylenes function by a similar 
mechanism, is discussed. 
2. MATERIALS AND METHODS 
Correspondence uddress: D. Kupfer, The Worcester Foundation for 
Experimental Biology, 222 Maple Ave., Shrewsbury, MA 01545, 
USA 
Male and female Sprague-Dawley CD rats were from Charles 
River Breeding Labs (Wilmin~on, MA). The males (90-100 g) were 
treated with phenobarbital (37.5 mg/kg i.p. in 0.2 ml Hz0 twice dai- 
ly) for 4 days. Liver microsomes were prepared 12-15 h after the last 
injection 1151. Female rats (20 or 21 days old) were used for induction 
of uterine ornithine decarboxylase (ODC). The rats wre ovariec- 
Published by Ekvier Science Publishers 3. V. (Biomedical Division) 
00145793/90/$3.50 0 1990 Federation of European Biochemical Societies 59 
Volume 261, number 1 FEBS LETTERS February 1990 
tomized and used 5-7 days later [16]. Briefly, rats were injected with 
the compounds and 6 h later the uteri were removed; individual uteri 
were homogenized and 20 OOG g supernate (half uterus equivalent) 
was incubated with [I-r4C]ornithine for 1 h. The reaction was ter- 
minated with 1 M citrate and the r4COz was trapped on filter paper 
strip containing 50 ~1 of NCS and quantitated by scintillation spec- 
trometry. 
2.1. Method to determine whether a compound is a proestrogen/ 
proantiestrogen 
The procedure, previously described by us [lO,ll], employs in the 
same vessel a metabolizing system (rat liver microsomes and 
NADPH) and an estrogen detecting system (rat uteri). A compound 
is considered to be a proestrogen/proantiestrogen if it requires 
metabolism (NADPH and active microsomes) to elevate the uterine 
estrogen receptor (BR) in the nuclei (ER.) and decrease the cytosolic 
ER (ER,). By contrast, a compound is considered to be active per se 
if such distribution of uterine ER occurs without metabolism 
(absence of NADPH or presence of heat-inactivated microsomes). 
Each incubation contained 3 ml Krebs-Ringer solution (KRS), about 
0.5 mg liver microsomal protein and halves of 6 uteri (sliced through 
the apex) and the test compound added in 5 pl ethanol; the control, 
lacking NADPH or containing heat-inactivated liver microsomes and 
NADPH, had the parallel halves of the same uteri. Prior to incuba- 
tion, oxygen is bubbled vigorously through the septum into the entire 
mixture for 2-3 min, to preserve receptor stability [29]. The reaction 
is started by injecting 0.3 mg NADPH in 0.3 ml KRS through the 
septem (controls receive 0.3 ml KRS). Incubation is conducted for 1 
h at 37°C with shaking. The uteri are washed, homogenized and the 
nuclei and 20000 g supernate are prepared. Quantitation of the 
estrogen receptor in the nuclei (ERJ and in the cytosol (ER,) was 
achieved by an exchange with [‘H]Ez [10,11,27]. 
3. RESULTS AND DISCUSSION 
It has been suggested that the triphenylethylenes 
tamoxifen and TACE are prodrugs [2,8,9]. We 
substantiated this for TACE. In vivo, TACE elicits 
estrogenic activity, elevating uterine weight and ODC 
(table 1). Similar estrogenic activity was observed with 
the antiestrogen-tamoxifen and with the estrogen- 
DES. However, in vitro, TACE did not inhibit the 
binding of [3H]E~ to the ER (not shown). Others also 
observed an extremely low binding affinity of TACE 
for ER, [28]. This indicates that TACE is a pro- 
estrogen. Nevertheless, TACE exhibits some ‘estro- 
genie’ effect on the ER in vitro, causing a moderate 
increase in the ER, (table 2); a similar effect was 
Table 1 
Effect of treatment of ovariectomized rats with TACE, tamoxifen or 
DES on uterine weight and ODC 
ODC activity 
CO2 evolved Uterine/body weight 
Treatment (pmol/uterus/h) xl00 
_ 17 * 3 (17) 38.0 * 1.5 (17) 
TACE 2089 + 156 (6) 64.2 + 4.2 (6)b 
Tamoxifen 1923 f 224 (6)a 68.6 f 3.5 (6)b 
DES 2549 & 307 (6)” 90.0 + 8.5 (6)b 
lntraperitoneal injections: TACE, 8 mg/kg BW; tamoxifen, 10 
mg/kg; DES, 0.03 mg/kg. Uteri were removed after 6 h, weighed and 
ODC determined for each uterus. aP<O.OO1; b P<O.O5. In paren- 
theses, numbers of animals. 
60 
Table 2 
Effect of incubations of TACE and tamoxifen with rat uteri (without 
liver microsomes) on the distribution of the uterine estrogen receptor 
in the cytosol (ER,) and nuclei (ER.) 
[3H]E2 bound/uterus (fmol) 
Compound ER, ER. ER, + ER, 
TACE, 2 PM’ 663 + 124 268 + 29* 931 
Tamoxifen, 2 pMb 472 271 743 
ControlC 887 + 45 82 + 8 969 ZL 54 
a Values represent mean * SE (3 experiments). bValues represent a 
single experiment. ’ Values represent mean f SE (7 experiments). 
* P<O.OOl. 
observed with tamoxifen. These effects were relatively 
small as compared with EZ and DES [lo]. It is unlikely 
that TACE and tamoxifen are metabolized by uterine 
monoxygenases into estrogens. Rat uteri do not exhibit 
significant 0-demethylating activity [ 10,l l] and, by 
contrast to mouse uteri [19], do not catalyze a certain 
aromatic hydroxylation [20]. Consequently, TACE and 
tamoxifen probably have weak estrogenic effects on the 
ER. 
TACE undergoes demethylation by rat liver micro- 
somal monooxygenase to phenolic products [21]. 
Hence, we anticipated that the incubation of TACE 
with liver microsomes will produce demethylated 
estrogenic metabolites which would markedly increase 
uterine ERn. However, it also seemed conceivable that 
the reactive intermediate of TACE (T*) [12,13] will 
bind covalently to the uterine ER, possibly at the 
estrogen binding site. In fact, when TACE was in- 
cubated with liver microsomes and NADPH in the 
presence of uteri (table 3), there was no increase in ER, 
but instead there was a pronounced decrease in total 
uterine ER, (ER, (ER, plus ERn)). There was no 
decrease in ERt when NADPH was deleted or when 
heat-inactivated liver microsomes were used. Further- 
more, there was a more pronounced decrease in ERt 
with increased concentration of TACE (Fig.1). These 
findings indicated that TACE metabolism was required 
for eliciting the diminished uterine ERt. Further studies 
Table 3 
Effect of incubation of TACE with rat liver microsomes and uteri on 
the uterine nuclear (ER.) and cytosolic (ERc) estrogen receptor 
[‘H]Ez bound/uterusa (fmol) 
TACE 
(1IM) NADPH ER, ER, ER, + ER, 
0.2 + 204.3~t45.5 (6)*138.2* 6.7 (8)378.7*28.7 (6)* 
0.2 - 610.8+42.8 (6) 95.9k11.2 (8)715.4+47.9 (9) 
0.2 + (boiled 680.8 (2) 121.7 (2) 802.4 (2) 
microsomes) 
a Values represents mean + SE. Number of experiments in paren- 
theses. 
*p< 0.001. 
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Fig.1. The effect of incubation of various concentrations of TACE 
with rat liver microsomes and uteri on total uterine ER (ER,). 
on whether the diminished ERt reflects a preferential 
decrease in ER, or ER, might yield information or ER 
trafficking. 
The pesticide methoxychlor is metabolized by liver 
microsomes into demethylated estrogenic products 
[ IO,1 1,311. We previously observed that methoxychlor, 
like TACE, can be metabolically activated to bind 
covalently to proteins [22,23]. However, by contrast to 
TACE [ 1.31, the reactive intermediate of methoxychlor 
(M*) did not bind to the exogenously added albumin 
(unpublished result). Therefore, M* was not expected 
to react with distant sites, such as uterine ER. In fact, 
the microsomal metabolism of methoxychlor increased 
ER, and decreased ER, without diminishing ERt 
[lO,l I] (table 4). Similarly MDDE, and in vivo meta- 
bolite of methoxychlor, did not affect ERt. Thus we 
concluded that whereas T* could inactivate ER, M* 
could not. Also this demonstrated that ER inactivation 
was not due to formation of other factors, unrelated to 
TACE metabolism. 
The decrease of ERt during the generation of T* was 
shown by the diminished binding of [3H] EZ in the ex- 
change assay. The possibility that TACE is metabolized 
Table 4 
Effect of hepatic mon~xygen~e mediated metabolism of TACE, 
methoxychlor and MDDE on the subcellular ~stribution of the 
uterine estrogen receptor in cytosol (ERc) and nuciei (ER3 
Microsomai [3H]Ea bound/uterus (fmol) 
Compound system ER, ER, ER, + ER, 
TACE’ Active 248 + 91* 133 zt,z 17 381 f 96* 
Inactive 610 * 134 211 4 8 821 f 134 
Methoxychlorb Active 986 262 1248 
Inactive 1211 89 1300 
MDWEb Active 359 375 734 
Inactive 696 97 793 
Each compound was at 2 pM. Active system, composed of PB rat 
liver microsomes (0.5 - 0.7 mg prot.). Inactive system lacked 
NADPH (TACE adn MDDE) or contained NADPH and heat- 
inactivated microsomes (methoxychlor). MDDE, i,l-dichforo-2,Z 
bis~-methox~henyl)ethene. a Values represent mean ti: SE (3 ex- 
periments). b Represent mean of two experiments. 
* P<O.O5. 
to a product with much higher affinity for the ER than 
Ez and thus interferes with the exchange of [3HJE~ is 
unlikely: (i) where unable to isolate such a metabolite 
from incubations of TACE with liver microsomes and 
(ii> increasing the concentration of [3H]E~ 5-fold and 
stripping the uterine cytosol with charcoa1 prior to the 
exchange assay did not alter the results (not shown). 
Currently, we have no information on whether the 
steroid-binding site is masked by T* or merely has 
become altered. Our previous studies suggest hat T* 
binds to the cysteine sulfhydryl in proteins ([ 121 and un- 
published data), Cysteine is present at the steroid-and 
DNA-binding sites of the ER ]14,18). Therefore it is 
possible that T* binds to the cysteines of the ER and in- 
terferes with E2 binding. An alternate, albeit less likely, 
interpretation of these results is that the metabolism of 
TACE has diminished the receptor level, by increasing 
its processing or by altering its structure possibly 
through a non-covalent binding mechanism. Nakao et 
al. [24] observed that the administration of tamoxifen 
to rats causes a dramatic decrease in uterine cytosolic 
estrogen-binding sites and elicits a modified ‘receptor’. 
This tempts a speculation that tamoxifen binds co- 
valently to the receptor in vivo. Our preliminary 
findings that tamoxifen undergoes metabolic activation 
by rat liver microsomes, resulting in covalent binding to 
protein (not shown), supports such a possibility. 
Previously, we demonstrated that the pretreatment of 
ovariectomized rats with tamoxifen abolishes the in- 
duction of ODC by a subsequent reatment with Ez 
[ZS]. Thus, it is conceivable that this desensitjzation 
might occur by a tamoxifen mediated inactivation of 
the ER. Whether TACE also could cause a desensitiza- 
tion of ODC induction, is not known. 
In conclusion, the current studies suggest a novel 
mechanism to explain the agonistic and antagonistic ac- 
tivity of triphenylethylenes. We propose that the two 
effects are the resultant of the reversible binding of 
estrogenic metabolites and of the reactive intermediate 
{RX). The dramatic species differences in response to 
tamoxifen could be due to qualitative or quantitative 
differences in RI formation, possibly because of species 
differences in P-450 isoforms, or due to species dif- 
ferences in quenching the RI. It would be of particular 
interest to determine whether the irreversible binding 
causes a partial or complete inactivation of the recep- 
tor. Alternatively, it is possible that the covalent bin- 
ding of TACE merely yields a persistently activated, 
albeit altered receptor, a mechanism proposed for the 
reaction of 1 (itu-hydroxyestrone [30]. The examination 
of these possibilities would require extensive in- 
vestigations. 
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